Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [7902]

ASCO 2019: No benefit from pazopanib in advanced kidney cancer after surgery to remove metastases

ASCO 2019: No benefit from pazopanib in advanced kidney cancer after surgery to remove metastases

ASCO 2019: New TAILORx data guides adjuvant therapy in younger breast cancer patients

ASCO 2019: New TAILORx data guides adjuvant therapy in younger breast cancer patients

ASCO 2019: International clinical trial of new drug for men with advanced prostate cancer yields strong result

ASCO 2019: International clinical trial of new drug for men with advanced prostate cancer yields strong result

ASCO 2019: Immunotherapy better than aggressive chemotherapy as first treatment option for recurrent head and neck cancer

ASCO 2019: Immunotherapy better than aggressive chemotherapy as first treatment option for recurrent head and neck...

ASCO 2019: NRG trial suggests total neoadjuvant therapy for locally advanced rectal cancer is safe

ASCO 2019: NRG trial suggests total neoadjuvant therapy for locally advanced rectal cancer is safe

ASCO 2019: NRG oncology trial of metformin for non-small cell lung cancer

ASCO 2019: NRG oncology trial of metformin for non-small cell lung cancer

ASCO 2019: T-VEC shows improved survival over cytokine therapy in patients with melanoma

ASCO 2019: T-VEC shows improved survival over cytokine therapy in patients with melanoma

ASCO 2019: Drug targeting DNA damage response shows promise against cancers of anus and genitals

ASCO 2019: Drug targeting DNA damage response shows promise against cancers of anus and genitals

ASCO 2019: Front-line pembrolizumab is promising alternative to chemotherapy for advanced gastroesophageal junction and gastric cancers

ASCO 2019: Front-line pembrolizumab is promising alternative to chemotherapy for advanced gastroesophageal...

ASCO 2019: Adding ribociclib to first-line endocrine therapy significantly improves survival for pre-menopausal women with advanced breast cancer

ASCO 2019: Adding ribociclib to first-line endocrine therapy significantly improves survival for pre-menopausal...

More from ecancer